Olszanski, A. J., Rasco, D. W., Sharma, M. R., Spira, A. I., Song, M. M., Pelster, M., Perez, C. A., Dowlati, A., Sanborn, R. E., Saif, M. W., Adkins, D., Lam, V. K., Kim, S. Y., Hecht, J. R., Raizer, J. J., Gregory, R. C., Casson, C. N., Ayyala, D. N., Sexauer, A., Champiat, S. (2026). A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 + regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3155